<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01980329</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00078492</org_study_id>
    <nct_id>NCT01980329</nct_id>
  </id_info>
  <brief_title>Polymorphic Effects of Cytochrome P450 3A5 on Pharmacokinetics of Maraviroc and Its Metabolites</brief_title>
  <official_title>Polymorphic Effects of Cytochrome P450 3A5 on Pharmacokinetics of Maraviroc and Its Metabolites</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the influence of genetic polymorphism of cytochrome
      P450 3A5 on pharmacokinetics of maraviroc and its oxidative metabolites
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to evaluate the effects of CYP3A5 genotype on pharmacokinetics of maraviroc
      and its oxidative metabolites. A single oral dose of 300 mg maraviroc will be given to 24
      eligible healthy individuals who will be screened and determined to have specific CYP3A5
      genotype - 8 homozygous wild type (2 CYP3A5*1 alleles), 8 heterozygous (1 CYP3A5*1 allele and
      1 mutant allele), and 8 without wild type genotype (2 mutant alleles). Blood samples will be
      drawn and urine samples will be collected immediately before and during a 32-hr period
      following the dose. The concentrations of maraviroc and its oxidative metabolites from the
      blood and urine samples will be measured and the pharmacokinetics of maraviroc and its
      metabolites will be compared among the three groups with different CYP3A5 polymorphic status.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve</measure>
    <time_frame>0-32 hour post dose administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clearance</measure>
    <time_frame>0-32 hr post dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma peak concentration</measure>
    <time_frame>0-32 hr post dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma half-life</measure>
    <time_frame>0-32 hr post dose administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary metabolic ratio</measure>
    <time_frame>0-32 hr post dose administration</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Cytochrome P450 CYP3A5 Enzyme Polymorphism</condition>
  <condition>Healthy Subjects</condition>
  <condition>Pharmacokinetics of Maraviroc</condition>
  <arm_group>
    <arm_group_label>Maraviroc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single oral administration of 300 mg maraviroc</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc</intervention_name>
    <arm_group_label>Maraviroc</arm_group_label>
    <other_name>Selzentry</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy with no acute medical illness

          -  Willing to provide written informed consent

          -  Age 18-65 years

          -  Negative serum pregnancy test (females only) at screening and a negative urine
             pregnancy test (females only) on day of dosing

          -  HIV seronegative at screening, as determined by any licensed ELISA

          -  At screening, no evidence of hepatic or renal impairment (LFT's &lt; 1.5 Upper Limit of
             Normal (ULN), creatinine clearance &gt; than 60 ml/min, total bilirubin below ULN, AST
             and ALT below 1.5 ULN)

          -  8 subjects with homozygous CYP3A5 allele *1 (wild type)

          -  8 subjects with 1 CYP3A5*1 allele and 1 mutant allele

          -  8 subjects with CYP3A5 allele other than *1

        Exclusion Criteria:

          -  Concomitant medication (prescription or over-the-counter) or herbal supplements for
             which there is a known risk of pharmacokinetic or pharmacodynamic drug interactions,
             including those that inhibit CYP3A4 as listed on the P450 Drug Interaction Table
             (http://medicine.iupui.edu/clinpharm/ddis/table.aspx)

          -  History of postural hypotension or cardiovascular disease

          -  Active medical or psychological condition that, in the opinion of the investigator,
             might put the volunteer at undue risk or interfere with the participation of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Namandje N Bumpus, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Craig W Hendrix, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Johns Hopkins University School of Medicine Division of Clinical Pharmacology</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2013</study_first_submitted>
  <study_first_submitted_qc>November 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2013</study_first_posted>
  <last_update_submitted>April 2, 2015</last_update_submitted>
  <last_update_submitted_qc>April 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Namandj√© N. Bumpus, PhD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>CYP3A5</keyword>
  <keyword>maraviroc</keyword>
  <keyword>polymorphism</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maraviroc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

